EMA Recommends Granting a Marketing Authorisation for Vimseltinib By Ogkologos - September 5, 2025 26 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults with symptomatic tenosynovial giant cell tumour Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Ibrutinib ESMO Highlights the Importance of Prioritising the Fight Against Cancer in Its Response to the Public Consultation on the EU4Health 2026 Work Programme ESMO Urges EU Policymakers to Protect the Wellbeing of the Oncology Workforce MOST POPULAR New on NCI’s Websites for March 2022 March 16, 2022 BRCA1/2 Pathogenic Variant Carriers with Serous Tubal Intraepithelial Carcinoma at Risk-Reducing... April 4, 2022 120 years of Cancer Research UK: how science transformed survival rates December 19, 2022 TP53 Allelic State is Critical in Myelodysplastic Syndromes August 4, 2020 Load more HOT NEWS Studies Assess Impact of Cancer Risk-Reduction Measures for People with BRCA... ESMO Congress 2024 Barcelona, Spain, 13-17 September Family Starts “Dancing While Cancering” To Honor Their Daughter’s Joyful Memory. Why Cancer Survivors Should Have a Written Survivorship Care Plan
